Poster Presentations
Apr 15, 2010
Poster Board Number
Category 5g. VIRAL HEPATITIS: g. HEPATITIS C - CLINICAL (THERAPY):
| TWELVE-WEEK COURSE OF PIFN-α-2A/RIBAVIRIN IS AN OPTIMIZED REGIMEN FOR TREATMENT OF HCV GENOTYPE 2 BUT NOT GENOTYPE 3 NON-CIRRHOTIC PATIENTS WITH RVR L.E. Adinolfi*, R. Zampino, B. Guerrera, L. Restivo, L. Rinaldi, A. Ciervo, V.R. Scialdone, M. Ferrara, G. Ruggiero Internal Medicine & Hepatology, Second University of Naples, Naples, Italy. *luigielio.adinolfi@unina2.it | 236 |
| SUSTAINED VIROLOGICAL RESPONSE (SVR) ACCORDING THE TYPE OF EARLY VIROLOGICAL RESPONSE (EVR) AND OTHER PROGNOSTIC FACTORS IN MONOINFECTED HCV AND COINFECTED HCV/HIV GENOTYPE 1 PATIENTS P.R.L.d. Almeida1*, A.A.D. Mattos2, C.V. Tovo3 1Internal Medicine, Hospital Nossa Senhora da Conceição, 2Gastroenterology, Santa Casa de Porto Alegre, 3Hospital Nossa Senhora da Conceição, Post-Graduation Course of UFCSPA, Porto Alegre, Brazil. *paulorlalmeida@terra.com.br | 237 |
| ANTIHCV TREATMENT OUTCOME IN DRUG USERS IS ASSOCIATED WITH BUPRENORFINE USE AND ADHERENCE TO TREATMENT O. Anagnostou1*, E. Tsirogianni2, I. Goulis3, A. Moursellas1, S. Kollia1, E. Petroulaki1, D. Dimitroulopoulos4, K. Micha1, S. Manolakopoulos5 1OKANA- Greek Organisation Against Drugs, Athens, 2OKANA- Greek Organisation Against Drugs, 3Aristoteleion University of Thessaloniki Medical School, Thessaloníki, 4Hellenic Anticancer Institute, 'Saint Savvas' Hospital, 5Athens University Medical School, Athens, Greece. *oanagnostou@yahoo.gr | 238 |
| SUSTAINED VIROLOGICAL RESPONSE PREVENTS DEVELOPMENT AND DELAYS PROGRESSION OF PORTAL HYPERTENSION IN HCV-RELATED LIVER CIRROSIS B.E. Annicchiarico1*, M. Siciliano1, A. Iacobellis2, A.W. Avolio3, G. Caracciolo1, A. Andriulli2, G. Bombardieri1 1Internal Medicine, Sacred Heart Catholic University, Roma, 2Gastroenterology, Casa Sollievo della Sofferenza Hospital, Foggia, 3Liver Transplantation Unit, Sacred Heart Catholic University, Roma, Italy. *terapiamedica@tin.it | 239 |
| SUSTAINED VIROLOGICAL RESPONSE IMPROVES SURVIVAL IN HCV-RELATED LIVER CIRROSIS WITH PORTAL HYPERTENSION B.E. Annicchiarico1*, M. Siciliano1, A. Iacobellis2, A.W. Avolio3, G. Caracciolo1, A. Andriulli2, G. Bombardieri1 1Internal Medicine, Sacred Heart Catholic University, Roma, 2Gastroenterology, Casa Sollievo della Sofferenza Hospital, Foggia, 3Liver Transplantation Unit, Sacred Heart Catholic University, Roma, Italy. *terapiamedica@tin.it | 240 |
| REDUCING ALPHA-FETOPROTEIN WITH INTERFERON THERAPY SUPPRESSES HEPATOCARCINOGENESIS IN HEPATITIS C VIRUS-INFECTED PATIENTS WHO ARE VIROLOGICAL RESPONDERS AND NON-RESPONDERS Y. Asahina*, K. Tsuchiya, N. Tamaki, M. Sato, T. Tanaka, I. Hirayama, Y. Yasui, K. Ueda, T. Kuzuya, H. Nakanishi, J. Itakura, M. Kurosaki, N. Izumi Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan. *asahina@musashino.jrc.or.jp | 241 |
| EFFECT OF HIGH-DOSE RIBAVIRIN (RBV), ALINIA (NITAZOXANIDE) AND PEGYLATED INTERFERON (PEGIFN) ALFA-2A IN ATTAINING SUSTAINED VIROLOGIC RESPONSE (SVR) IN TREATMENT OF CHRONIC HEPATITIS C P. Basu1*, K. Rayapudi2, N.J. Shah3, T. Pacana3, N. Krishnaswamy3, R. Brown Jr1 1Columbia University Medical Center, Manhattan, 2Vassar Brothers Hospital, Poughkeepsie, New York 12601, Poughkeepsie, 3North Shore University Hospital at Forest Hills, Forest Hills, NY, USA. *patbasumd@aol.com | 242 |
| ENDOGENOUS ERYTHROPOIETIN RESPONSE AND PREDICTIVE FACTORS FOR ANEMIA DURING TREATMENT WITH PEG-INTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS L.G. van Vlerken1, H. van Soest1, M.P. Janssen2, G.J. Boland1,3*, J.P.H. Drenth4, D.M. Burger5, P.D. Siersema1, K.J. van Erpecum1 1Department of Gastroenterology and Hepatology, 2Julius Center for Health Sciences and Primary Care, 3Department of Virology, University Medical Center Utrecht, Utrecht, 4Department of Gastroenterology and Hepatology, 5Clinical Pharmacy Department, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. *g.j.boland@umcutrecht.nl | 243 |
| RIBAVIRIN- RATHER THAN PEG-INTERFERON-RELATED FACTORS ARE PREDICTING NON-RESPONSE TO ANTIVIRAL THERAPY IN NAIVE CHRONIC HEPATITIS C PATIENTS L.G. van Vlerken1, E.J. Huisman1, H. van Soest1, G.J. Boland1,2*, P.D. Siersema1, D.M. Burger3, K.J. van Erpecum1 1Department of Gastroenterology and Hepatology, 2Department of Virology, University Medical Center Utrecht, Utrecht, 3Clinical Pharmacy Department, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. *g.j.boland@umcutrecht.nl | 244 |
| HIGH VIRAL RESPONSE IN A MULTIDISCIPLINARY NETWORK NOT ORGANIZED UNDER ONE ROOF FOR ANTIVIRAL MANAGEMENT OF CHRONIC HEPATITIS C VIRAL PATIENTS INFECTED AFTER SUBSTANCE USE S. Bourgeois1*, W. Schrooten2,3, G. Robaeys4,5,6, Belgian Network on Hepatitis in Substance Users 1Gastro-enterology, ZNA Stuivenberg, Antwerpen, 2Ziekenhuis Oost Limburg, Genk, 3UHasselt, Diepenbeek, 4Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, 5Hepatology, UZ Leuven, Leuven, 6Medicine, UHasselt, Diepenbeek, Belgium. *stefan.bourgeois@zna.be | 245 |
| ASSESSMENT OF PAROXETINE IN THE PREVENTION OF DEPRESSION IN PATIENTS WITH CHRONIC HEPATITIS C TREATED BY PEG-INTERFERON-RIBAVIRIN.: A DOUBLE-BLINDED, RANDOMIZED STUDY. ANRS HC18 PAROPEG J.-P. Bronowicki1*, V. Canva2, A. Tran3, M.-N. Hilleret4, S. Pol5, M. Mainard6, M. Bourlière7, V. de Ledinghen8, A. Abergel9, K. Barange10, N. Ganne11, P. Cales12, V. Di Martino13, O. Goria14, J.-M. Molina15, L. Alric10, J.-J. Raabe16 1CHU de Nancy, Vandoeuvre-lès-Nancy, 2CHU de Lille, Lille, 3CHU de Nice, Nice, 4CHU de Grenoble, Grenoble, 5Hopital Cochin, Paris, 6CHU de Lyon, Lyon, 7Hopital Saint Joseph, Marseille, 8CHU de Bordeaux - Hopital Pellegrin, Bordeaux, 9CHU de Clermont Ferrand, Clermont Ferrand, 10CHU de Toulouse, Toulouse, 11Hopital Jean Verdier, Bondy, 12CHU Angers, Angers, 13CHU de Besançon, Besançon, 14CHU de Rouen, Rouen, 15Hopital Saint-Louis, Paris, 16CHR Metz, Metz, France. *jp.bronowicki@chu-nancy.fr | 246 |
| PREDICTING TREATMENT OUTCOME AMONG SLOW RESPONDERS: A RETROSPECTIVE ANALYSIS OF THE SUCCESS STUDY M. Buti1*, V.G. Morozov2, V.V. Rafalskiy3, F. Wong4, J. Sumskiene5, X. Yu6, R. Faruqi6, L.D. Pedicone6, R. Esteban7 1Dept. of Internal Medicine - Hepatology, Liver Unit Hospital General Universitario Valle Hebron and Ciber-ehd del Instituto Carlos III, Barcelona, Spain, 2Hepatolog Medical Center, Samara, 3Smolensk State Medical Academy, Smolensk, Russia, 4Toronto General Hospital, Toronto, ON, Canada, 5Clinic of Gastroenterology, Kaunas, Lithuania, 6Schering Corp., a Division of Merck & Co., Kenilworth, NJ, USA, 7Liver Unit Hospital General Universitario Valle Hebron and Ciber-ehd del Instituto Carlos III, Barcelona, Spain. *14100abf@comb.cat | 247 |
| PREVENTIVE EFFECT OF ANTI-VIRAL THERAPY ON THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C OR B: A META-REGRESSION APPROACH C.C. Cheng1,2*, Y.C. Shen1,2,3, C. Hsu2,3, F.C. Hu1,2, A.L. Cheng2,3,4 1Department of Medical Research, 2National Center of Excellence for Clinical Trial and Research, 3Department of Oncology, 4Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan R.O.C.. *chiachi@ntuh.gov.tw | 248 |
| ACCURATE PERSONALIZATION OF PEG-IFN+RBV TREATMENT DURATION BASED ON THE DECLINE OF HCV INFECTED CELLS COMPUTED DURING THE 1ST MONTH OF THERAPY P. Colombatto1*, V. Romagnoli1, L. Civitano1, P. Ciccorossi1, A.M. Maina1, F. Oliveri1, B. Coco1, B. Cherubini1, F. Bonino2,3, M.R. Brunetto1 1University Hospital of Pisa, 2University of Pisa, Pisa, 3Foundation IRCCS “Policlinico” of Milan, Milano, Italy. *p.colombatto@ao-pisa.toscana.it | 249 |
| HEPATITIS C TREATMENT IN PATIENTS WITH GENOTYPE 2/3: 16 VS. 24 WEEKS; ANALYSIS OF OUTCOME, HRQOL, DIRECT AND INDIRECT COSTS T. Dal Bianco1*, A. Grasso2, A. Carlotto3, F. Malfatti2, A.M. Miotti4, M.T. Giordani4, A. Tramarin4, P. Fabris4 1Dept. of Medicine, Hospital of Monfalcone, Monfalcone, 2Dept. of Medicine, Hospital of Savona, Savona, 3Dept. of Infectious Diseases, Hospital of Schio, Schio, 4Infectious Diseases and Tropical Medicine, S. Bortolo Hospital, Vicenza, Italy. *tdelbian@tin.it | 250 |
| GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF GENOTYPE 2/3 HCV VARIANTS IN PATIENTS TREATED WITH TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN STUDY C209 S. De Meyer1*, G.R. Foster2, A. Ghys1, M. Beumont1, B. Van Baelen1, T.-I. Lin1, G. Picchio3 1Tibotec BVBA, Mechelen, Belgium, 2Queen Mary University of London, Institute of Cell and Molecular Science, London, UK, 3Tibotec Inc, Yardley, PA, USA. *sdmeyer@its.jnj.com | 251 |
| 2-LOG DROP IN VIRAL LOAD AT ONE MONTH: A NEW STOPPING RULE IN RELAPSERS AND NON-RESPONDERS HCV PATIENTS RE-TREATED WITH PEGYLATED-IFN AND RIBAVIRIN? P. Deltenre1,2*, M. Corouge1, V. Canva1, M. El Nady1, A. Louvet1,3, H. Castel1, W. Faustine1, S. Dharancy1,3, J. Henrion2, P. Mathurin1,3 1Service d'Hépato-Gastroentérologie, Hôpital Huriez, Lille, France, 2Service d'Hépato-Gastroentérologie, Hopital de Jolimont, Haine-Saint-Paul, Belgium, 3INSERM U795, Lille, France. *pierre.deltenre@skynet.be | 252 |
| ASSOCIATION OF HOST PHARMACODYNAMIC EFFECTS AND VIROLOGIC RESPONSE TO PEGINTERFERON ALFA-2A/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C R.T. Chung1, A. Di Bisceglie2*, F.F. Poordad3, T. Hassanein4, X. Zhou5, E. Lentz6, A. Prabhakar6, F.M. Hamzeh6 1Massachusetts General Hospital, Boston, MA, 2Saint Louis University School of Medicine, St. Louis, MO, 3Cedars Sinai Medical Center, Los Angeles, 4University of California San Diego, San Diego, CA, 5RTI Health Solutions, Research Triangle Park, NC, 6Genentech, South San Francisco, CA, USA. *dibiscam@slu.edu | 253 |
| MANAGEMENT OF CHRONIC HEPATITIS C IN CHILDREN: A CONTINUOUS DEBATE A. El Sherbini* Research Unit, Tanta Fevers' Hospital, Tanta, Egypt. *azza_el_sherbini@yahoo.com | 254 |
| EFFICACY AND SAFETY OF PEGUILATED INTERFERON AND RIBAVIRIN IN HCV-INFECTED PATIENTS WITH ADVANCED CIRRHOSIS AWAITING LIVER TRANSPLANTATION A.C.C.A. Feldner*, T.C.R. Ribeiro, M.A. Bragagnolo-Jr, J. Seda-Neto, J.D.R. Brito, L.Z. Trindade, E.M.G. Oliveira, E.R. Parise, M. Kondo Gastroenterology, Federal University of São Paulo, São Paulo, Brazil. *amaralfeldner@terra.com.br | 255 |
| BASELINE CHARACTERISTICS AND ON-TREATMENT PREDICTORS OF RESPONSES FROM REAL-WORLD PATIENT COHORTS: INTERIM RESULTS OF THE MULTINATIONAL PROPHESYS COHORTS P. Ferenci1*, M.L. Shiffman2, M. Puoti3, A. Orlandini4, F.A. Caruntu5, D. Ouzan6, M. Bozic7, M. Bourliere8, G.F. Silva9, J. Schuller10, J.-P. Mulkay11, A. Horban12, D. Messinger13, A. Tietz14, A. Mangia15 1Medical University of Vienna, Vienna, Austria, 2Bon Secours Health System, Liver Institute of Virginia, Newport News, VA, USA, 3University of Brescia, Brescia, 4Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy, 5Matei Bals Infectious Diseases Institute, Bucharest, Romania, 6Institut Arnault Tzanck, Saint-Laurent-du-Var, France, 7Clinical Center of Serbia, Beograd, Serbia, 8Hospital Saint Joseph, Marseille, France, 9Botucatu School of Medicine, Botucatu, Brazil, 10Szent Laszlo Hospital, Budapest, Hungary, 11Hôpital Saint Pierre, Bruxelles, Belgium, 12Medical University Clinic of Infectious Diseases, Warsaw, Poland, 13IST GmbH, Mannheim, Germany, 14Roche, Basel, Switzerland, 15Hospital Casa Sollievo della Sofferenza, Rotondo, Italy. *peter.ferenci@meduniwien.ac.at | 256 |
| SELDI PROTEINCHIP SERUM ANALYSIS TO PREDICT VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON PLUS RIBAVIRIN N. Fujita1*, K. Mihara2, J. Mukai2, Y. Yanohara2, R. Sugimoto1, Y. Kobayashi1, Y. Naito3, T. Ichida4, M. Kaito5, T. Yoshikawa3, Y. Takei1 1Department of Gastroenterology and Hepatology, Institute of Medical Sciences, Mie University Graduate School of Medicine, Mie, 2Biomarker Science Co. Ltd., Osaka, 3Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, 4Department of Gastroenterology, Juntendo University School of Medicine, Shizuoka Hospital, Shizuoka, 5Mie Gastroenterological Clinic, Mie, Japan. *nfujita@clin.medic.mie-u.ac.jp | 257 |
| ASSOCIATION OF SERUM INTERFERON-GAMMA INDUCIBLE PROTEIN 10 (IP-10) LEVELS WITH VIROLOGICAL RESPONSE TO PEGYLATED INTERFERON ALFA-2B PLUS RIBAVIRIN THERAPY FOR HCV GENOTYPE 1 INFECTION M. Fukuda*, H. Yatsuhashi, I. Takahara, T. Murata, S. Hashimoto, A. Nishikawa, S.K. Bae, Y. Motoyoshi, S. Nagaoka, K. Yanagi, S. Abiru, A. Komori, K. Migita, H. Fujioka, H. Ishibashi Clinical Research Center, NHO National Nagasaki Medical Center, Nagasaki, Japan. *mfukuda@nmc.hosp.go.jp | 258 |
| ANTIVIRAL EFFICACY OF RIBAVIRIN MONOTHERAPY FOLLOWED BY STANDARD COMBINATION TREATMENT IN CHRONIC HEPATITIS C B. Fülöp1*, U. Mihm2, B. Schlosser1, M. Biermer1, A. Brodzinski1, F. van Bömmel1, P. Rhode3, P. Buggisch4, C. Sarrazin5, T. Berg1 1Hepatology and Gastroenterology, Charite Virchow Clinic, Berlin, 2Gastroenterology and Hepatology, Johann Wolfgang Goethe University Medical Center, Frankfurt/Main, 3Gastroenterology and Hepatology, St Marien Hospital Hamm, Hamm, 4Hepatology, IFI, Institute for Interdisciplinary Medicine at Asclepios Clinic St. Georg, Hamburg, 5Gastroenterology and Hepatology, Johann Wolfgang Goethe University Medical Center, Berlin, Germany. *balazs.fulop@charite.de | 259 |
| SUCCESSFUL THERAPY WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN CAUSES A SUSTAINED DECREASE IN PORTAL PRESSURE IN PATIENTS WITH CHRONIC HEPATITIS C-RELATED CIRRHOSIS M. Garcia-Retortillo1*, D. Rincón2, A. Albillos3, J. Colmenero1, R. Bataller1, J.L. Calleja4, R. Bañares2, J.G. Abraldes1, J. Bosch1, J.M. Sanchez-Tapias1, X. Forns1, J.C. Garcia-Pagán1, CIBERehd Spain 1Liver Unit, Hospital Clínic, Barcelona, 2Hospital Gregorio Marañón, 3Hospital Ramón y Cajal, 4Hospital Puerta de Hierro, Madrid, Spain. *97235@imas.imim.es | 260 |
| INDIVIDUALIZED TREATMENT STRATEGIES AND MULTIDISCIPLINARY SUPPORT PROGRAMS (MSP) INCREASE THE EFFICACY OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C M. García-Retortillo1*, I. Cirera1, N. Cañete1, M.D. Giménez1, C. Márquez1, P. Castellví1, R. Navinés2, J.R. Castaño3, O. Urbina4, E. Salas4, S. Coll1, F. Bory1, R. Martín-Santos2, R. Solà1 1Liver Section, Hospital del Mar / IMIM / Universitat Autònoma de Barcelona, 2Department of Psychiatry and CIBERSAM, Institut Clínic de Neurociències / Hospital Clínic / IDIBAPS, 3Psychiatry Service, Hospital del Mar, 4Pharmacy Service, Hospital del Mar / IMIM, Barcelona, Spain. *97235@imas.imim.es | 261 |
| FLUVASTATIN AS OUT-OF LABEL ENHANCER FOR EARLY (EVR) AND SUSTAINED (SVR) VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON AND RIBAVIRIN E. Georgescu*, D. Catu, R.M. Stoica, R.I. Ionescu Internal Medicine 1/Gastroenterology - Filantropia University Hospital, University of Medicine and Pharmacy of Craiova, Craiova, Romania. *efg@usa.net | 262 |
| RAPID VIROLOGICAL RESPONSE IS A PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEP C G3 PATIENTS TREATED WITH PEGASYS AND RBV U. Adeeb, F. Khattak, M.L. Gill* Hepatology, Maroof International Hospital, Islamabad, Pakistan. *gill95@yahoo.com | 263 |
| INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A AND/OR RIBAVIRIN ARE ASSOCIATED WITH HIGHER RATES OF SVR AND LOWER RELAPSE RATES AMONG PATIENTS WITH METABOLIC SYNDROME S.A. Harrison1*, M.L. Shiffman2, M. Rodriguez-Torres3, D. Abdurakhmanov4, G.F. Silva5, C. Stanciu6, W. Mazur7, S.V. Feinman8, C. Moreno9, M. McKenna10, D. Messinger11, A. Teitz12, K.R. Reddy13, On behalf of the PROGRESS Study Investigators 1Brooke Army Medical Center, Houston, TX, 2Bon Secours Health System, Liver Institute of Virginia, Newport News, VA, 3Fundacion de Investigacion de Diego Santurce, Santurce, PR, USA, 4Moscow Medical Academy, Moscow, Russia, 5Botucatu School of Medicine, Botucatu, Brazil, 6Gastroenterology and Hepatology Institute, Iasi, Romania, 7Medical University of Silesia, Chorzów, Poland, 8Mt. Sinai Hospital, Toronto, ON, Canada, 9Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium, 10Roche, Welwyn, UK, 11IST GmbH, Mannheim, Germany, 12Roche, Basel, Switzerland, 13Hospital of the University of Pennsylvania, Philadelphia, PA, USA. *stephen.a.harrison@us.army.mil | 264 |
| SEQUENCE HETEROGENEITY OF NS5A OF HCV GENOTYPES 2A AND 2B AFFECTS RVR AND SVR TO PEG-IFN/RBV COMBINATION THERAPY H. Hotta1*, A. El-Shamy1, S.R. Kim2, S. Imoto2, C. Aoki3, Y. Ide1, I. Shoji1 1Division of Microbiology, Kobe University Graduate School of Medicine, 2Division of Gastroenterology, Kobe Asahi Hospital, Kobe, 3The Intitute of Medical Science, The University of Tokyo, Tokyo, Japan. *hotta@kobe-u.ac.jp | 265 |
| CLINICAL MARKERS OF THE METABOLIC SYNDROME ARE ASSOCIATED WITH HCV GENOTYPE 1 INFECTION AND ARE STRONG NEGATIVE PREDICTORS OF EARLY VIROLOGICAL RESPONSE E. Jaeckel1*, E. Zehnter2, C. John3, T. Lutz4, W. Schmidt5, R. Link6, P. Geyer7, G. Teuber8, M. Stern9, H.R. Bruch10, K.H. Hey11, R. Heyne12, B. Moeller12, G. Bellmann13, A. Schober14, S. Stoll15, M.P. Manns1 1Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, 2Center of Gastroenterology, Dortmund, 3Center of Gastroenterology, Berlin, 4Infektiologikum, Frankfurt, 5MVZ-Aerzteforum Seestrasse Dres. C. Mayr / PD W. Schmidt, Berlin, 6Clinic for Internal Medicine, St. Josefs Hospital, Offenburg, 7Center of Gastroenterology, Huenfeld, 8IFS, Stresemannallee 3, Frankfurt/M, 9Center of Internal Medicine, Frankfurt, 10Center of Gastroenterology, Bonn, 11Center of Gastroenterology, Paderborn, 12Center of Gastroenterology and Livercenter, 13General Practice, Berlin, 14Center of Gastroenterology, Goettingen, 15Roche Pharma AG, Grenzach-Wyhlen, Germany. *jaeckel.elmar@mh-hannover.de | 266 |
| CYSTATIN C MEASUREMENT MAY IDENTIFY ASYMPTOMATIC RENAL DYSFUNCTION IN CHRONIC HEPATITIS C PATIENTS J. Jaroszewicz*, M. Rogalska, T. Szulzyk, R. Flisiak Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland. *jaroszewicz.jerzy@gmail.com | 267 |
| RELATIONSHIP OF SERUM IP-10 LEVELS WHICH REFLECTS HEPATIC INTERFERON STIMULATING GENE INDUCTION AND ANTIVIRAL EFFECT OF PEG/RBV COMBINATION THERAPY IN PATIENT WITH CHRONIC HEPATITIS C Y. Karino*, J. Toyota, T. Arakawa, Y. Kuwata, J. Akaike, I. Ozeki, T. Sato, T. Ohmura Hepatology Unit, Sapporo Kosei General Hospital, Sapporo, Japan. *ykarino@jcom.home.ne.jp | 268 |
| DYNAMICS OF APOPTOTIC ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH ALBINTERFERON ALFA-2B OR PEGINTERFERON ALFA-2A B. Kronenberger1*, E. Herrmann1, C. Chen2, M. Fiscella2, G. Subramanian2, J. McHutchison3, Y. Benhamou4, M. Sulkowski5, D. Nelson6, S. Zeuzem1, for the ACHIEVE Study Group 1J.W. Goethe University Hospital, Frankfurt/Main, Germany, 2Human Genome Sciences, Inc., Rockville, MD, 3Duke Clinical Research Institute, Durham, NC, USA, 4Hôpital Pitié-Salpêtrière, Paris, France, 5Johns Hopkins Center for Viral Hepatitis, Baltimore, MD, 6University of Florida, Gainesville, FL, USA. *bernd.kronenberger@email.de | 269 |
| PREDICTIVE MODEL OF RESPONSE TO PEGINTERFERON IN CHRONIC HEPATITIS C: IMPACT OF MUTATIONS IN ISDR AND CORE REGION REVEALED BY CLASSIFICATION AND REGRESSION TREE ANALYSIS M. Kurosaki1*, N. Sakamoto2, M. Iwasaki3, M. Sakamoto4, Y. Suzuki5, N. Hiramatsu6, F. Sugauchi7, A. Tamori6, N. Izumi8 1Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 2Tokyo Medical and Dental University, 3Seikei University, Tokyo, 4University of Yamanashi, Yamanashi, 5Toranomon Hospital, Tokyo, 6Osaka University Graduate School of Medicine, Osaka, 7Nagoya City University Graduate School of Medical Sciences, Nagoya, 8Musashino Red Cross Hospital, Tokyo, Japan. *kurosaki@musashino.jrc.or.jp | 270 |
| EXTENDED TREATMENT OF TREATMENT-NAïVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1-INFECTION AND SLOW RESPONSE TO PEGYLATED INTERFERON-ALFA AND RIBAVIRIN: A META-ANALYSIS C.M. Lange*, H. Farnik, C. Sarrazin, B. Kronenberger, S. Zeuzem, E. Herrmann Department of Medicine 1, J. W. Goethe-University Hospital, Frankfurt/Main, Germany. *lange_christian1@yahoo.de | 271 |
| EARLY VIRAL RESPONSE OF CONTROLLED-RELEASE INTERFERON ALPHA2B AND RIBAVIRIN VS. PEGYLATED-INTERFERON ALPHA2B AND RIBAVIRIN IN TREATMENT-NAÏVE GENOTYPE1 HEPATITIS C: 12 WEEK RESULTS (SELECT-2 TRIAL) E. Lawitz1*, Z. Younossi2, P. Mehra3, A. Rigney4, Z. Krastev5, K. Tchernev6, D. Takov7, W.A. Long4 1Alamo Medical Research, San Antonio, TX, 2Inova Health Systems, Falls Church, VA, 3eStudy Site, Chula Vista, CA, 4Biolex Therapeutics, Pittsboro, NC, USA, 5UMHAT 'St. Ivan Rilski', 6UMHAT 'Alexandrovska', 7Military Medical Academy, Sofia, Bulgaria. *lawitz@alamomedicalresearch.com | 272 |
| SHORT TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF GS‑9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH CHRONIC HCV INFECTION M.P. Manns1*, E. Lawitz2, A.I.M. Hoepelman3, H.J. Choi4, J.Y. Lee4, M. Cornpropst5, W. Liang5, B. King5, K.R. Hirsch5, D. Oldach5, F.S. Rousseau5 1Dept. Gastroenterology, Hepatology & Endocrinology, Medical School Hannover, Hannover, Germany, 2Alamo Medical Research, San Antonio, TX, USA, 3Department of Internal Medicine & Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands, 4LG Life Sciences, Ltd, Seoul, Republic of Korea, 5Gilead Sciences, Inc, Durham, NC, USA. *manns.michael@mh-hannover.de | 273 |
| IMPROVED SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN “DIFFICULT-TO-CURE” PATIENTS TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: AN ANALYSIS FROM THE PROVE3 STUDY M.P. Manns1*, A.J. Muir2, N. Adda3, J.G. McHutchison2, N. Terrault4, L. Bengtsson3, S. George3, A.M. Di Bisceglie5 1Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, 2Duke University Medical Center, Durham, NC, 3Vertex Pharmaceuticals Incorporated, Cambridge, MA, 4University of California San Francisco, San Francisco, CA, 5St. Louis University School of Medicine, St. Louis, MO, USA. *manns.michael@mh-hannover.de | 274 |
| TREATMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS WITH COMPENSATED LIVER CIRRHOSIS L. Martin Carbonero*, P. Tuma, E. Vispo, J. Medrano, P. Labarga, J. González-Lahoz, P. Barreiro, V. Soriano Infectious Diseases, Hospital Carlos III, Madrid, Spain. *lmcarbonero@gmail.com | 275 |
| WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV G.V. Matthews1*, J. Grebely1, M. Hellard2, B. Yeung1, P. Marks1, W. Rawlinson3, J. Kaldor1, G.J. Dore1, ATAHC Study Group 1National Centre in HIV Epidemiology and Clinical Research (NCHECR), University of New South Wales, Sydney, NSW, 2Burnet Institute, Melbourne, VIC, 3Virology Division, SEALS Microbiology, Prince of Wales Hospital, Sydney, NSW, Australia. *gmatthews@nchecr.unsw.edu.au | 276 |
| GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS J.G. McHutchison1*, Z.D. Goodman2, G.T. Everson3, I.M. Jacobson4, T.D. Boyer5, E.R. Schiff6, W.M. Lee7, R.M. Chasen8, J.M. Vierling9, E.J. Lawitz10, M. Kugelmas11,12, N.C. Tsai13, R.J. Buynak14, A.M. Sheikh15, B. Armstrong16, T.C. Rodell17, D. Apelian17 1Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, 2AIP Laboratories, Silver Spring, MD, 3University of Colorado Denver, Aurora, CO, 4Department of Medicine, Weill Cornell Medical College, New York, NY, 5University of Arizona, Tucson, AZ, 6Center for Liver Diseases, University of Miami, Miami, FL, 7University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 8Maryland Digestive Disease Research, Laurel, MD, 9Baylor College of Medicine, Houston, 10Alamo Medical Research, San Antonio, TX, 11South Denver Gastroenterology, PC, 12Center for Disease of the Liver and Pancreas, Swedish Medical Center, Englewood, CO, 13University of Hawaii, Honolulu, HI, 14NW Indiana Center for Clinical Research, Valparaiso, IN, 15Gastrointestinal Specialists of Georgia, Marietta, GA, 16QST Consultations, LTD, Allendale, MI, 17GlobeImmune, Inc., Louisville, CO, USA. *mchut001@mc.duke.edu | 277 |
| PEGYLATED INTERFERON PLUS RIBAVIRIN: AN EFFICACIOUS AND WELL-TOLERATED TREATMENT REGIMEN FOR HIV-HCVCO-INFECTED PATIENTS WITH HEPATITIS C VIRUS RELATED CIRRHOSIS M.C. Mendes-Correa1*, M.H. da Silva2,3, J.F.C. Figueiredo4, G. Gryninger5, M. Gonzalez6, T. Reuter7, L.G.M. Filho3, A.C.S. Santos2, J.D.U. Brito8, F. Nogui2,9, R.J. Gianini10, P.A. Ferreira11 1Hospital das Clinicas-Infectious Diseases Department, Sao Paulo University Medical School, 2CRTAIDS, Sao Paulo, 3Clinica de Especialidades, Sao Bernardo do Campo, 4Infectious Diseases Department, Sao Paulo University Medical School, Ribeirao Preto, 5CRTAIDS, Bauru, 6Instituto de Infectologia Emilio Ribas, Sao Paulo, 7Infectious Diseases Department, Medical School -Espirito Santo Federal University, Vitória, 8CRTAIDS, Brasília, 9CRTAIDS, Diadema, 10Epidemiology and Statistics Laboratory, Sao Paulo University Medical School, 11Infectious Diseases Department, Medical School -Sao Paulo Federal University, Sao Paulo, Brazil. *cassiamc@uol.com.br | 278 |
| PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN A DOSE-RANGING PHASE 1B STUDY IN HEPATITIS C PATIENTS K.A. Byrnes-Blake1, J.A. Freeman1, M.G. Dodds1, L. Rapalus1, S. Pederson1, N. Hunder2, D.M. Miller1* 1Preclinical Development, 2Clinical Development, ZymoGenetics, Inc., Seattle, WA, USA. *desm@zgi.com | 279 |
| RETREATMENT WITH PEG-IFN ALPHA-2A PLUS RIBAVIRIN FOR 48 WEEKS IN CHRONIC HEPATITIS C GENOTYPE 2 AND 3 RELAPSERS TO A PREVIOUS ANTIVIRAL TREATMENT E. Minola1*, V. Baldo2, T. Baldovin3, A. Floreani3 1A.O. Ospedali Riuniti, Bergamo, 2Dept of Public Health, University of Padova, 3Dept of Surgical and Gastroenterological Sciences, Padova, Italy. *eliseominola@tiscali.it | 280 |
| SAFETY AND PHARMACOKINETICS OF A NOVEL HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE E2 GLYCOPROTEIN OF HEPATITIS C VIRUS (MBL-HCV1) IN HEALTHY VOLUNTEERS B.A. Leav, S. Sloan, B.M. Blair, P. Cheslock, M. Knauber, D.M. Ambrosino, D.C. Molrine* MassBiologics, University of Massachusetts Medical School, Boston, MA, USA. *deborah.molrine@umassmed.edu | 281 |
| A SPECIFIC HAPLOTYPE AT THE ENT1 GENE INFLUENCES THE RATE OF SUSTAINED VIROLOGICAL RESPONSE TO PEGINTERFERON-RIBAVIRIN IN HIV/HCV-COINFECTED PATIENTS J. Morello*, L. Cuenca, V. Soriano, J. Medrano, G. González-Pardo, E. Álvarez, A. Madejón, J. González-Lahoz, S. Rodríguez-Nóvoa Hospital Carlos III, Madrid, Spain. *judit_morello@yahoo.es | 282 |
| HCV PROTEASE INHIBITOR RESTORES INSULIN SENSITIVITY IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS R. Moucari1*, N. Forestier2, D. Larrey3, D. Guyader4, P. Couzigou5, Y. Benhamou6, H. Voitot7, M. Vidaud7, S. Seiwert8, B. Bradford8, S. Zeuzem9, P. Marcellin1 1Service d'Hépatologie and INSERM U773, Beaujon Hospital, AP HP, Clichy, France, 2Saarland University Hospital, Homburg, Germany, 3CHU Montpellier, Montpellier, 4CHU Rennes, Rennes, 5CHU Bordeaux, Bordeaux, 6Pitié Salpêtrière University Hospital, Paris, 7Beaujon Hospital, AP HP, Clichy, France, 8InterMune, Inc., San Francisco, CA, USA, 9J.W. Goethe University Hospital, Frankfurt, Germany. *rami.moucari@inserm.fr | 283 |
| LIPID MODULATORS (STATINS AND EICOSAPENTAENOIC ACID) ACCELERATE THE DECLINE OF HCV VIRUS LOAD DURING TREATMENT WITH PEG-INTERFERON AND RIBAVIRIN M. Nakamuta1*, T. Yoshimoto1, S. Harada1, T. Ohashi1, N. Fukushima1, K. Fukuizumi1, T. Fujino1, H. Nishi1, T. Mizutani1, N. Harada1, H. Nomura2, M. Enjoji3 1Gastroenterology, Clinical Research Center, Kyushu Medical Center, National Hospital Organization, Fukuoka, 2Department of Gastroenterology, Shin-Kokura Hospital, Kitakyushu, 3Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan. *nakamuta@kyumed.jp | 284 |
| INDIVIDUALISED, COST-EFFECTIVE HCV TREATMENT - THE TAILORED TAUNTON ALGORITHM ACHIEVES EQUAL SVR WITH LESS WEEKS OF COMBINED ANTI-VIRAL THERAPY M. Naseer1*, W.R. Matull2, A. Tarr2, P. Thomas2, S. Pugh2 1Gastroenterology, Royal Liverpool University Hospital, Liverpool, 2Gastroenterology, Musgrove Park Hospital, Taunton, UK. *naseerkk@hotmail.com | 285 |
| EXPOSURE-RESPONSE RELATIONSHIP OF FILIBUVIR IN HCV INFECTED PATIENTS: APPLICATION TO DOSE SELECTION FOR COMBINATION THERAPY S. Neelakantan1*, V.S. Purohit2, M. O'Gorman1, J. Hammond2, T.G. Tensfeldt1 1Primary Care, 2Specialty Care, Pfizer Inc., New London, CT, USA. *srividya.neelakantan@pfizer.com | 286 |
| EVALUATING VIROLOGIC RESPONSE WITHIN 2-4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT A. Neumann1,2*, M. Shiffman3, P. Ferenci4, G. Foster5, E. Yoshida6, S. Pianko7, M. Sulkowski8, S. Zeuzem9, Y. Benhamou10, D. Nelson11, J. McHutchison12, E. Pulkstenis13, G. Subramanian13, for the ACHIEVE Study Group 1Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel, 2Institute for Theoretical Biology, Humboldt University, Berlin, Germany, 3Virginia Commonwealth University Medical Center, Richmond, VA, USA, 4Medical University of Vienna, Vienna, Austria, 5The Royal London Hospital, London, UK, 6University of British Columbia, Vancouver, BC, Canada, 7Monash Medical Centre, Clayton, VIC, Australia, 8Johns Hopkins Center for Viral Hepatitis, Baltimore, MD, USA, 9J.W. Goethe-University Hospital, Frankfurt/Main, Germany, 10Hôpital Pitié-Salpêtrière, Paris, France, 11University of Florida, Gainesville, FL, 12Duke Clinical Research Institute, Durham, NC, 13Human Genome Sciences, Inc., Rockville, MD, USA. *neumann@mail.biu.ac.il | 287 |
| INFRADURE: SUSTAINED DELIVERY OF INTERFERON-ALPHA (IFNα) IN SCID MICE BY IMPLANTED IFNA SECRETING DERMAL BIOPUMPS E. Shoshani1, B. Stern1, A. Pearlman1*, P. Ng2, R. Meari1, H. Goltzmann1, E. Keeffe3 1Medgenics, Inc, Misgav, Israel, 2Molecular Genetics, Baylor College of Medicine, Houston, TX, 3Stanford University Medical Center, Stanford, CA, USA. *alppearlman2@gmail.com | 288 |
| DISCREPANCIES BETWEEN DEFINITIONS OF NULL RESPONSE TO TREATMENT WITH PEGINTERFERON- ALFA-2A AND RIBAVIRIN: IMPLICATIONS FOR NEW HCV DRUG DEVELOPMENT G. Picchio1*, D. Luo1, S. George2, A. Kwong2, T. Kieffer2, J. Mc Hutchison3, J.-M. Pawlotsky4 1Tibotec, Inc, Yardley, PA, 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, 3Duke University Medical Center, Durham, NC, USA, 4Hôpital Henri Mondor, Créteil, France. *gpicchio@its.jnj.com | 289 |
| EARLY VIROLOGICAL RESPONSE PROFILES WITH TELAPREVIR (T) IN COMBINATION WITH PEGINTERFERON-ALFA-2A (P) AND RIBAVIRIN (R) IN GENOTYPE 1 HCV TREATMENT-NAïVE AND TREATMENT-EXPERIENCED PATIENTS ARE SIMILAR F. Poordad1*, J.G. McHutchison2, M.L. Shiffman3, T. Berg4, A.J. Muir2, M.P. Manns5, A.M. Di Bisceglie6, N. Terrault7, G. Picchio8, A. Kwong9, L. Bengtsson9, S. George9, N. Adda9 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Duke University Medical Center, Durham, NC, 3Bon Secours Health System, Liver Institute of Virginia, Newport News, VA, USA, 4University Clinic, Leipzig, 5Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, 6St. Louis University School of Medicine, St. Louis, MO, 7University of California San Francisco, San Francisco, CA, 8Tibotec, Inc., Yardley, PA, 9Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA. *fred.poordad@cshs.org | 290 |
| INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY G.M. Prati1*, M.G. Rumi1, A. Aghemo1, R. D'Ambrosio1, S. De Nicola1, L. Olgiati2, M.F. Donato1, M. Colombo1 11st Division of Gastroenterology, 2Division of Endocrinology, Fondazione IRCCS Maggiore Hospital Università degli Studi di Milano, Milan, Italy. *gianmaria.prati@unimi.it | 291 |
| IMPACT OF HIGHER DOSES OF PEGINTERFERON ALFA-2A AND RIBAVIRIN ON RVR, CEVR AND SVR IN HCV G1 PATIENTS WITH VIRAL LOADS ≥400 000IU/ML WEIGHING ≥85KG K.R. Reddy1*, M.L. Shiffman2, M. Rodriguez-Torres3, D. Abdurakhmanov4, I. Bakulin5, G.F. Silva6, H. Cheinquer7, M. Rabbia8, M. McKenna9, A. Tietz10, S.A. Harrison11, On behalf of the PROGRESS Study Investigators 1Hospital of the University of Pennsylvania, Philadelphia, PA, 2Bon Secours Health System, Liver Institute of Virginia, Newport News, VA, 3Fundacion de Investigacion De Diego Santurce, Santurce, PR, USA, 4Moscow Medical Academy, 5State Postgraduate Medical Institute, Ministry of Defence of the Russian Federation, Moscow, Russia, 6Botucatu School of Medicine, Botucatu, 7Hospital de Clinicas de Porto Alegre, Porte Alegre, Brazil, 8Roche, Nutley, NJ, USA, 9Roche, Welwyn, UK, 10Roche, Basel, Switzerland, 11Brooke Army Medical Center, Houston, TX, USA. *rajender.reddy@uphs.upenn.edu | 292 |
| PREDICTORS OF RELAPSE AMONG PATIENTS TREATED WITH STANDARD OR INDUCTION DOSE PEGINTERFERON ALFA-2A (40KD) COMBINED WITH STANDARD OR HIGHER DOSE RIBAVIRIN IN DIFFICULT-TO-CURE PATIENTS K.R. Reddy1*, M.L. Shiffman2, M. Rodriguez-Torres3, I. Bakulin4, H. Cheinquer5, A. Horban6, M. El-Kashab7, L. Gheohge8, P. Buggisch9, M. Rabbia10, M. McKenna11, S.A. Harrison12, On behalf of the PROGRESS Study Investigators 1Hospital of the University of Pennsylvania, Philadelphia, PA, 2Bon Secours Health System, Liver Institute of Virginia, Newport News, VA, 3Fundacion de Investigacion de Diego Santurce, Puerto Rico and Ponce School of Medicine, Santurce, PR, USA, 4State Postgraduate Medical Institute, Ministry of Defence of the Russian Federation, Moscow, Russia, 5Hospital de Clinicas de Porto Alegre, Porte Alegre, Brazil, 6Medical University Clinic of Infectious Diseases, Warsaw, Poland, 7Toronto Liver Centre, Toronto, ON, Canada, 8Fundeni Clinical Institute, Bucharest, Romania, 9University Medical Center Hamburg‐Eppendorf, Hamburg, Germany, 10Roche, Nutley, NJ, USA, 11Roche, Welwyn, UK, 12Brooke Army Medical Center, Houston, TX, USA. *rajender.reddy@uphs.upenn.edu | 293 |
| HVPG MEASUREMENT IN CIRRHOTIC HCV CAN BE USED TO PREDICT OUTCOME AND SAFETY OF ANTIVIRAL THERAPY T. Reiberger1*, K. Rutter1, A. Ferlitsch1, H. Hofer1, S. Beinhardt1, A.F. Staettermayer1, M. Kundi2, P. Ferenci1, M. Peck-Radosavljevic1 1Internal Medicine III, Div. of Gastroenterology & Hepatology, 2Center for Public Health, Medical University Vienna, Vienna, Austria. *thomas.reibeger@meduniwien.ac.at | 294 |
| POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE OF ALBINTERFERON ALFA-2B M. Riggs1*, T. Bergsma1, J. Rogers1, M. Gastonguay1, G. Subramanian2, C. Chen2, M. Devalaraja2, A. Corey2 1Metrum Research Group LLC, Tariffville, CT, 2Human Genome Sciences, Inc., Rockville, MD, USA. *mattr@metrumrg.com | 295 |
| PEGINTERFERON ALFA-2A (40KD) PLUS 800 OR 1000/1200 MG/DAY RBV IN G1 HIV-HCV-CO-INFECTED PATIENTS: EARLY RESPONSES TO TREATMENT AND PREDICTABILITY FOR SVR IN THE PARADIGM STUDY M. Rodriguez-Torres1*, J. Slim2, L. Bhatti3, R.K. Sterling4, T. Hassanein5, B. Clotet6, T. Branco7, A. Bertasso8, S. Stancic8, M.S. Sulkowski9, On behalf of the PARADIGM Study Investigators 1Fundacion de Investigacion de Diego Santurce, Puerto Rico and Ponce School of Medicine, Santurce, PR, 2St. Michael's Medical Center, Newark, NJ, 3Aids Healthcare Foundation, LA, CA, 4Virginia Commonwealth University, Richmond, VA, 5University of California San Diego, San Diego, CA, USA, 6Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 7Hospital Fernando da Fonseca, Amadora, Portugal, 8Roche, Nutley, NJ, 9Johns Hopkins University School of Medicine, Baltimore, MD, USA. *rodztorres@coqui.net | 296 |
| PREDICTIVE FACTORS FOR SILIBININ MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND NONRESPONSE TO PEG-IFN/RBV THERAPY K. Rutter1*, A. Stättermayer1, T. Reiberger1, J. Aberle2, K. Zinober1, T.-M. Scherzer1, S. Beinhardt1, H. Holzmann2, P. Steindl-Munda1, H. Hofer1, P. Ferenci1 1Gastroenterology and Hepatology, 2Clinical Virology, Medical University of Vienna, Vienna, Austria. *karoline.rutter@meduniwien.ac.at | 297 |
| ESCITALOPRAM FOR THE PREVENTION OF PEG-IFN-α AND RIBAVIRIN ASSOCIATED DEPRESSION IN HCV-INFECTED PATIENTS: FINAL RESULTS FROM THE CIPPAD-TRIAL M. Schaefer1,2*, R. Sarkar2, V. Weich3, S. Effenberger2, L. Heinze2, U. Spengler4, T. Schlaepfer5, J. Ockenga6, P. Buggisch7, J. Reimer8, R. Link9, O. Kummer10, K. Lieb11, H. Weidenbach12, M. Rentrop13, T. Discher14, G. Fromm15, S. Zeuzem16, T. Berg3 1Klinik für Psychiatrie, Psychotherapie und Suchtmedizin, Kliniken Essen-Mitte, Essen, 2Klinik für Psychiatrie, Campus Mitte, Charité, Universitätsmedizin Berlin, 3Klinik für Gastroenterologie und Hepatologie, Charité Universitätsmedizin, Campus Virchow-Klinikum, Berlin, 4Medizinische Klinik II, 5Klinik für Psychiatrie, Universitätsklinik Bonn, Bonn, 6Medizinische Klinik II, Klinikum Bremen-Mitte, Bremen, 7Medizinische Klinik I, 8Klinik für Psychiatrie, UKE Hamburg, Hamburg, 9Medizinische Klinik, St. Josefs Klinik Offenburg, Offenburg, 10Abteilung Innere Medizin II, Universität Freiburg, Freiburg, 11Klinik für Psychiatrie, Universitätsklinikum Mainz, Mainz, 12II. Medizinische Klinik und Poliklinik, 13Klinik für Psychiatrie, Technische Universität München, München, 14Medizinische Klinik und Poliklinik II, 15Klinik für Psychiatrie, Universitätsklinik Giessen, Giessen, 16Medizinische Klinik I, Goethe Universitätsklinik, Frankfurt/Main, Germany. *m.schaefer@kliniken-essen-mitte.de | 298 |
| BASELINE CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF RIBAVIRIN >800 MG/DAY AMONG G2/3 PATIENTS PRESCRIBED PEGINTERFERON ALFA-2A (40KD) FROM REAL-WORLD PATIENT COHORTS: INTERIM RESULTS FROM PROPHESYS M.L. Shiffman1*, P. Ferenci2, T. Hassanein3, M. Curescu4, C. Coppola5, J. Pruthi6, R. Aires7, G. Lengyel8, S. Pol9, D. Nelson10, D. Messinger11, A. Tietz12, G.M. Dusheiko13 1Bon Secours Health System, Liver Institute of Virginia, Newport News, VA, USA, 2Medical University of Vienna, Wien, Austria, 3University of California, San Diego, CA, USA, 4University of Medicine and Pharmacy Timisoara, Timisoara, Romania, 5Unità Operativa Epatologia ed Ecografia Interventistica Ospedale Gragnano, Naples, Italy, 6High Desert Gastroenterology Suite B, Lancaster, CA, USA, 7The Goiás Federal University Clinical Hospital, Gioânia, Brazil, 82nd Dept. of Medicine, Semmelweis University, Budapest, Hungary, 9Hospital Necher, Paris, France, 10University of Florida, Gainesville, FL, USA, 11IST GmbH, Mannheim, Germany, 12Roche, Basel, Switzerland, 13Royal Free and University College School of Medicine, London, UK. *mlshiffman@googlemail.com | 299 |
| PHASE 1B DOSE-ESCALATION STUDY OF SD-101, A NOVEL THERAPEUTIC TLR-9 AGONIST, IN TREATMENT-NAïVE CHRONIC HEPATITIS C PATIENTS J. Cianciara1, J.T. Martin2, M.C. Spellman3* 1Dept of Hepatology and Acquired Immunodeficiencies, Warsaw Medical University, Warszawa, Poland, 2Dynavax Technologies, Berkeley, 3Medical Consultant, Dynavax Technologies, San Francisco, CA, USA. *mspellman@comcast.net | 300 |
| INFRADURE: SUSTAINED INTERFERON-ALPHA (IFNα) PRODUCTION AND DELIVERY BY DERMAL MICROORGAN BIOPUMPS B. Stern1*, E. Shoshani1, A. Pearlman1, P. Ng2, R. Meari1, H. Goltzmann1, E. Keeffe3 1Medgenics, Inc., Misgav, Israel, 2Molecular Genetics, Baylor College of Medicine, Houston, TX, 3Stanford University Medical Center, Stanford, CA, USA. *baruchstern@yahoo.com | 301 |
| IMPACT OF A HIGH RIBAVIRIN DOSE PER WEIGHT ON RESPONSE TO RETREATMENT AFTER RELAPSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN C. Stern*, M. Martinot-Peignoux, M.P. Ripault, A.-C. Cardoso, R.J. Carvalho-Filho, N. Boyer, P. Marcellin Service d'Hépatologie, Hôpital Beaujon, Clichy, France. *christiane.stern@gmail.com | 302 |
| SHIFTS IN CHILD-PUGH SCORE IN PATIENTS COINFECTED WITH HIV-HCV UNDERGOING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN ARE NOT PREDICTIVE OF HEPATIC DECOMPENSATION M. Sulkowski1*, R.T. Chung2, J. Slim3, L. Bhatti4, R. Sterling5, T. Hassanein6, R. Serrão7, R. Solà8, A. Bertasso9, S. Stancic9, M. Rodriguez-Torres10, on behalf of the PARADIGM Study Investigators 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3St. Michael's Medical Center, Newark, NJ, 4Aids Healthcare Foundation, LA, CA, 5Virginia Commonwealth University, Richmond, VA, 6University of California San Diego, San Diego, CA, USA, 7Hospital São João, Porto, Portugal, 8Hospital del Mar, Barcelona, Spain, 9Roche, Nutley, NJ, 10Fundacion de Investigacion De Diego Santurce,Puerto Rico and Ponce School of Medicine, Santurce, PR, USA. *msulkows@jhmi.edu | 303 |
| METABOLIC SYNDROME (MS) IS A NEGATIVE PREDICTOR OF TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE IDEAL STUDY M.S. Sulkowski1*, J.W. King2, S.A. Harrison3, L. Rossaro4, K.-Q. Hu5, E.J. Lawitz6, M.L. Schiffman7, A.J. Muir8, G.W. Galler9, J. McCone10, L.M. Nyberg10, W.M. Lee11, R. Ghalib12, J.G. McHutchison8, S. Noviello13, V.S. Goteti13, J.K. Albrecht13, C.A. Brass13 1Viral Hepatitis Center, Johns Hopkins University School of Medicine, Baltimore, MD, 2Louisiana State University Health Sciences Center, Shreveport, LA, 3Brooke Army Medical Center, Fort Sam Houston, TX, 4University of California Davis Medical Center, Sacramento, 5University of California-Irvine Medical Center, Irvine, CA, 6Alamo Medical Research, San Antonio, TX, 7Bon Secours Health System, Liver Institute of Virginia, Newport News, VA, 8Duke Clinical Research Institute, Durham, NC, 9Kelsey-Seybold Research Foundation, Houston, TX, 10Southern California Permanente Medical Group, San Diego, CA, 11University of Texas Southwestern Medical Center at Dallas, 12The Liver Institute at Methodist Dallas, Dallas, TX, 13Schering Corp., a Division of Merck & Co., Kenilworth, NJ, USA. *msulkowski@jhmi.edu | 304 |
| TREATMENT-INDUCED ANEMIA PREDICTS SVR AMONG ALL HCV-GENOTYPES TREATED WITH PEG-IFN α-2B AND RIBAVIRIN: MARKED DIFFERENCES BETWEEN FEMALE AND MALE G. Teuber1*, S. Mauss2, E. Zehnter3, M.P. Manns4, T. Dahhan5, S. Kaiser6, U. Meyer7, T. Witthöft8, B. Möller9, N. Dikopoulos10, J. Brack11, M. Bilzer12, G. Tossing12, D. Hüppe13, BNG Hepatitis Study Group 1Johann Wolfgang Goethe-University, Frankfurt, 2Medical Group Practice, Düsseldorf, 3Gastroenterological Practice, Dortmund, 4Medical High School Hannover, Hannover, 5Medical Practice, Backnang, 6University of Tübingen, Tübingen, 7Medical Practice, Berlin, 8University of Lübeck, Lübeck, 9Leberzentrum, Medical Practice, Berlin, 10University of Ulm, Ulm, 11Hospital Nord Ochsenzoll, Hamburg, 12Essex Pharma GmbH, München, 13Medical Group Practice, Herne, Germany. *gerlinde.teuber@em.uni-frankfurt.de | 305 |
| RELATION OF INSULIN RESISTANCE AND HEPATIC STEATOSIS WITH ADVANCED HEPATIC FIBROSIS IN PATIENTS WITH GENOTYPE 1 OR 2/3 CHRONIC HEPATITIS C A. Thompson1*, M. Grigorescu2, R. Flisiak3, A. Horban4, M. Buti5, V. Rehak6, K. Han7, R. Safadi8, M. Cho9, M. Torbenson10, G. Subramanian11, J. McHutchison12, for the ACHIEVE Study Group 1GI/Hepatology Research Program, Duke Clinical Research Institute, Durham, NC, USA, 2Spitalul Clinic de Urgenta 'Prof Dr Octavian Fodor', Cluj-Napoca, Romania, 3Wojewódzki Szpital Specjalistyczny, Bialystok, 4Wojewódzki Szpital Zakaźny, Warszawa, Poland, 5Vall d'Hebron University Hospital, Barcelona, Spain, 6Nuselská Poliklinika-Remedis, Prague, Czech Republic, 7Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 8Hadassah Medical Center, Jerusalem, Israel, 9Pusan National University, Yangsan Hospital, Busan, Republic of Korea, 10Johns Hopkins Center for Viral Hepatitis, Baltimore, 11Human Genome Sciences, Inc., Rockville, MD, 12Duke Clinical Research Institute, Durham, NC, USA. *alexander.thompson@duke.edu | 306 |
| HIGH PREVALENCE OF PRE-EXISTING ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEPATITIS C (HCV) PATIENTS WHICH IS NOT ASSOCIATED WITH IMPAIRED RESPONSE TO PEG-INTERFERON H. Tillmann1*, N.J. Ganson2, K. Patel1, A.J. Thompson1, M. Abdelmalek1, T. Moody2, J.G. McHutchison1, M.S. Hershfield2 1GI/Hepatology, 2Division of Rheumatology, Duke Clinical Research Institute, Duke University, Durham, NC, USA. *hans.tillmann@duke.edu | 307 |
| VIROLOGIC AND METABOLIC RESPONSES IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH INSULIN RESISTANCE (IR) TREATED WITH PIOGLITAZONE AND PEGINTERFERON ALFA-2A PLUS RIBAVIRIN S. Harrison1, F.M. Hamzeh2, E. Lentz2, J.M. Vierling3* 1Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Houston, TX, 2Genentech US Medical Affairs, Genentech, South San Francisco, CA, 3Director of Baylor Liver Health and Chief of Hepatology, Baylor College of Medicine, Houston, TX, USA. *vierling@bcm.tmc.edu | 308 |
| COMPARISON OF EFFICACY BETWEEN PEGINTERFERON ALFA-2A OR -2B PLUS RIBAVIRINE IN THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN DAILY ROUTINE: RESULTS FROM PRACTICE T. Witthoeft1*, S. Mauss2, D. Hueppe3, C. John4, R. Heyne5, B. Moeller5, R. Link6, A. Herrmann7, A. Baumgarten4, A. Dikopoulos8, G. Teuber9 1Center of Gastroenterology, Stade, 2Center for HIV and Hepatogastroenterology, Duesseldorf, 3Center for Gastroenterology, Herne, 4Center of Gastroenterology, Practice of Internal Medicine, 5Center of Gastroenterology and Livercenter, Berlin, 6Internal Medicin, St. Josefs-Krankenhaus, Offenburg, 7Internal Medicine II, Friedrich-Schiller-Universitaet, Jena, 8Klinik fuer Innere Medizin I, Universitaetsklinikum Ulm, Ulm, 9Interdisziplinäres Facharztzentrum Sachsenhausen, Frankfurt/Main, Germany. *dr.thomas.witthoeft@t-online.de | 309 |
| MARKED SPIROMETRY DECLINE IN PATIENTS WITH CHRONIC HEPATITIS C DURING TREATMENT WITH ALBINTERFERON ALFA-2B IS SIMILAR TO PEGINTERFERON ALFA-2A S. Zeuzem1*, M. Sulkowski2, D. Nelson3, Y. Benhamou4, Y. Yin5, G. Feutren6, P. Noble7, J. McHutchison8, for the ACHIEVE Study Group 1J.W. Goethe University Hospital, Frankfurt/Main, Germany, 2Johns Hopkins Center for Viral Hepatitis, Baltimore, MD, 3University of Florida, Gainesville, FL, USA, 4Hôpital Pitié-Salpêtrière, Paris, France, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7Duke University School of Medicine, 8Duke Clinical Research Institute, Durham, NC, USA. *zeuzem@em.uni-frankfurt.de | 310 |